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Abstract Tuberous sclerosis (TSC) is an inherited disorder best known for its associationwith severe learning di⁄-
culties, epilepsy, behavioural problems, skin and renal pathology. Lymphangioleiomyomatosis (LAM), characterized by
alveolar smooth muscle proliferation and cystic destruction of parenchyma, occurs as an infrequent symptomatic pul-
monary complication inTSC and as a very rare sporadic disease in thosewithout signs of TSC.Considered a generalized
andprogressive cystic lungdisease that is di⁄culttotreatwith a poorprognosis, it hasbeenreported almostexclusively
inwomen, most commonly presenting with dyspnoea and pneumothorax in those of childbearing age.We investigated
theclinical featuresandprognosisof LAMinpatientswithTSCincluding thee¡ectsoftreatment, strati¢edby themethod
of diagnosis of LAM (i.e. histological or radiological).We found histological proof of diagnosis in10 of 21patientswithTSC
andsymptomatic lungdisease, onsetinchildhoodinfour, threemaleswith LAM, individualswith apparently focaldisease,
great variation in clinical course and no clear treatment bene¢t. In those withTSC, symptomatic LAMis infrequent but
causes a signi¢cantmorbidity andmortality.It was not possible to detect predisposing factors, other thanbeing female.
Maleswith apparent LAM should be rigorously investigated.r2002 Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1206, available online athttp://www.idealibrary.comon
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Tuberous sclerosis (TSC) is an autosomal dominant dis-
order with a birth incidence of around one in 10 000 (1)
and a spontaneous mutation rate of B65%. Initially
thought to be a rare condition of unknown aetiology
with a characteristic facial skin rash, severe epilepsy and
severe learning di⁄culties, it has become apparent that
the disease is genetic and is more diverse than originally
recognized.More than a quarter of patients have neither
epilepsy nor severe learning di⁄culties, but can have se-
verely a¡ected o¡spring.
Lutembacher ¢rst described lymphangioleiomyoma-
tosis (LAM) inTSC in1918, althoughhemistook the cystic
and nodular changes for metastasis from renal ¢brosar-
coma. In 1939, Berg and Vejilens gave the ¢rst accurate
and clear description of pulmonary tuberous sclerosis.
Dwyer (2) described three cases of LAM inTSC and re-
viewed a further 31 cases, and Castro (3) made a retro-
spective study of nine patients. Other reports of LAMReceived 3 July 2001and accepted13 August 2001
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Johnson (4) recently reviewed LAM.
LAM predominantly a¡ects females of childbearing
age (5).Themostcommonpresenting symptoms aredys-
pnoea (from pneumothorax and chylothorax), chronic
cough, haemoptysis, wheeze and chest pain, but asymp-
tomatic cases occur (2). It can lead to cyanosis, respira-
tory failure and cor pulmonale (2^5). Pulmonary
function tests show an obstructivemore often than a re-
strictive pattern (6).Treatment of LAM is di⁄cult, and is
usually symptomatic. Hormone manipulation has been
triedbutwithout consistent success (3,7).The long-term
prognosis is often considered poor with many patients
following a relentless deterioration after the onset of
their symptoms (2).
We aimed to document the clinical features of LAM in
a cross-sectional study of patients with a diagnosis of
TSC and LAM.
METHODS
Patients su¡ering from symptomatic pulmonary compli-
cations of TSCwere identi¢ed from several U.K. sources:
8 RESPIRATORYMEDICINEthe BathTSC clinic (with records on 395 TSC patients),
Respiratory Physicians in the Wessex region, theTuber-
ous Sclerosis Association, the Medical Genetics Depart-
ment in Cardi¡ and the Renal Medicine Department in
Brighton.
Patients were classi¢ed as having ‘de¢nite’ LAM if the
diagnosis had been con¢rmed by histopathology at post
mortem or following lung biopsy,‘probable’ LAM if they
hadmultiple thinwalled cysts on high resolution compu-
terised tomography (HRCT) scan or honeycombing or
¢ne reticular shadowing on chest X-ray. If their only evi-
dence of LAMwas of a pneumothorax, they were classi-
¢ed ashaving ‘possible’ LAM.Patientswere considered to
have de¢niteTSC according to the strict interpretation
of the recently revised criteria for clinical diagnosis (8),
suggesting two independent hamartomas are required
to make a con¢dent diagnosis, but counting LAM and
renal angiomyolipomas as one harmartoma for this
purpose.
Clinical records and, wherepossible, radiographic ¢lms
were reviewed. Age at diagnosis, diagnostic criteria and
familyhistoryof TSC; age atonset, symptoms anddiagno-
sis of lung disease, mode of presentation, complications,
chest X-ray, HRCT and biopsy appearances, pulmonary
function tests, extrapulmonarymanifestations, treatment
and outcomewere noted. All patients still living were as-
sessedby interview and examination and, where not pre-
cluded by the severity of learning di⁄culties, basic lung
functionwasmeasuredusing a portable spirometer. Ahis-
tory was taken from the relatives of all decreased pa-
tients. Ethical permission was obtained for the study
from the Bath Local Research Ethics Committee.
RESULTS
Twenty-onepatientswithTSC (20with de¢niteTSC) and
pulmonary disease were identi¢ed (Table1).Ten patients
had de¢nite LAM, con¢rmed at post mortem in four.
Their histology showed smooth muscle proliferation,
honeycomb lung or multiple cysts and bullae (Table 2).
Nine patients had probable LAM con¢rmed by HRCT in
six and chest X-ray in three, two honeycombing and one
with ¢ne reticular shadowing (on chest X-ray).Two cases
hadpneumothoraces only on chest X-ray andHRCT had
not been performed (one with probable TSC). All
patients had facial angio¢bromas plus at least one other
hamartoma (in addition to LAM) and de¢nite TSC,
except patient 21 who was an obligate carrier for TSC,
with an a¡ected sister and son (and her mother had un-
gual ¢bromata); shehad twohypopigmentedmaculesbut
had not undergone fundoscopy, renal or cranial imaging.
Presenting features and age at diagnosis of TSC and
LAM are shown inTable 1. Eighteen of the 21 cases were
female and seven were known to have familial TSC.
Median age of diagnosis of TSC was 17 years (range 6weeks^3 years).Three had a diagnosis of TSCmade as a
result of their pulmonary disease.Themedian age of on-
set of pulmonary symptoms was 20 years (range birth^
34 years). The median age of diagnosis of LAM was 25
years (range 6 months^ 50 years).Therewas a mean de-
lay of 6 years between the onset of respiratory symp-
toms and the eventual diagnosis of LAM (range 0^30
years). The most common presentation was acute dys-
pnoea, secondary topneumothorax in14 (¢vebilaterally)
and to chylothorax in one.Five other patients presented
with chronic dyspnoea and one patient presented with
thick bronchopulmonary secretions as an infant. Dys-
pnoea occurred in19, cough in15, wheeze in11, haemop-
tysis in six and pain in 13, usually in conjunction with
pneumothoracies (Table 2). Seventeen su¡ered pneu-
mothoraces, four chylothoraces, one a pericardial e¡u-
sion and one a fatal pulmonary haemorrhage (Table 2).
Four patients died as a result of their respiratory dis-
ease. Patient1had bilateral pneumothoracies at 25 years
and gradually deteriorated, dying at the age of 47 years
from cor pulmonale. Patient 2 had a left pneumothorax
aged 18 years, bilateral pneumothoracies aged 21 years
and subsequently complained of shortness of breath and
su¡ered recurrent chest infections, dying of respiratory
failure aged 27 years. Patient 3 developed bilateral pneu-
mothoracies during general anaesthesia for gastroscopy
at18 years of age, dying of respirator failure1week later.
Patient 4 presentedwith a left-sidedpneumothorax at19
years of age following a 1-week history of a dry cough.
She was treated conservatively and allowed home to
await HRCT. She su¡ered an acute fatal pulmonary hae-
morrhagewhilst asleep.
Spirometry could only be performed on 11 patients.
Two had normal lung function, three an obstructive pic-
ture, and six a restrictive pattern.Response to broncho-
dilators was notmeasured.
Nine patients underwent pleurodesis and four pleur-
ectomy for recurrent or severe pneumothoracies.With
little or no improvement in symptoms sevenpatientshad
bronchodilator inhalers and two inhaled steroids in addi-
tion. Four patients received progesterone therapy. Pa-
tient two su¡ered from increasing dyspnoea and
recurrent chest infections from the age of 22 years.Her
condition deteriorated before, during and after1year of
treatment with progesterone. Patient 10 had bilateral
pneumothoracies aged 30 years treated by pleurodesis.
Depo progesterone (as depo-provera) was started and
has continued for 5 years. She has remained symptoma-
tically stable with mild dyspnoea, wheeze on exertion
and occasional cough.Patient12 hadworsening dyspnoea
and haemoptysis over a 16-year period. Since depo
progesterone was commenced, her exercise tolerance
improved and there has been no deterioration in her
lung function tests. Patient 14 had a renal haemorrhage
at 35 years, treated by transfusion and with depot pro-
gesterone, but 4 years later su¡ered a pneumothorax
TABLE 1. Sex, age at whichTSCwas diagnosed, reason fordiagnosis of TSC, age of onset and presenting features of pulmonary
disease, strati¢edbyde¢nite, probable andpossible diagnosis of LAM
Patient Sex Age atdiagnosis
of TSC
Reason for
diagnosis of TSC
Age of diagnosis
of pulmonary
symptoms
Presenting
feature(s) of LAM
Patientswith a de¢nite diagnosis of LAM
1 Female 16 years Retinalphakoma 25 years Pnuemothorax
(bilateral)
2 Female 4 years Facial angio¢broma CT brain 18 years Pnuemothorax
3 Female 2 years Infantile spasms CT brain 18 years Pnuemothorax
(bilateral)
4 Female 3 years Epilepsy CT brain 19 years Pnuemothorax
5 Female 9 months Facial angio¢broma 7 years Dyspnoea
6 Female 37 years Investigated followingdiagnosis
of son
Teenager Dyspnoea and
chest pain
7 Male 6 months PulmonaryTSC 6months Thickpulmonary
secretions
8 Female 18 months Infantile spasms CT brain 21years Pnuemothorax
(bilateral)
9 Female 34 years PulmonaryTSC 10 years Dyspnoea and
weight loss
10 Female 30 years PulmonaryTSC 30 years Pnuemothorax
(bilateral)
Patientswith a probable diagnosis of LAM
11 Female 21years Investigated followingdiagnosis
of daughter.
34 years Dyspnoea
12 Female 11months Infantile spasms CT brain 19 years Pnuemothorax
13 Female 5 years Facial angio¢broma CT brain 32 years Pnuemothorax
14 Female 35 years Renalhaemorrhage 38 years Chylothorax
15 Female 17 years Investigated followingdiagnosis
of son
17 years Pnuemothorax
(bilateral)
16 Female 37 years Ungual ¢broma Facial
angio¢broma
23 years Pnuemothorax
17 Female 24 years Investigated followingdiagnosis
of son
20 years Pnuemothorax
18 Male 6 weeks Epilepsy CT brain 8 years Dyspnoea and
drycough
19 Male 21years Epilepsy CT brain 32 years Pnuemothorax
Patientswith a possible diagnosis of LAM
20 Female 6 years Facial angio¢broma 20 years Pnuemothorax
21 Female 28 years Obligate carrier.Twohypomelanic
patches
25 years Pnuemothorax
LYMPHANGIOLEIOMYOMATOSISANDTUBEROUSSCLEROSIS 9and chylous e¡usion. A course of oral steroids was pre-
scribed for patients 3 and 16, with no improvement,
although patient 17 made a remarkable recovery from
acute respiratory failure after treatment with steroids
(seeTable 3).
Two patients died within days of developing respira-
tory symptoms; the remaining patients were followed
up for an average of 14 years (median of 10 years, range
6months^38 years).Five have shown a progressive dete-
rioration, two dying from their disease. There sympto-
matic patients improved and two remained stable whilenine patients were asymptomatic after the presenting
episode.
Othermanifestations of TSC
All patients had skin manifestations of TSC. Fourteen
had known renal involvement with angiomyolipomas.
One had renal involvement found incidentally at post
mortem, two patients had undergone nephrectomy, the
other 11 patients had AML7 cysts on renal ultrasound
scan. Only two of the asymptomatic patients had been
TABLE 2. Symptoms, complications and investigations
Patient Dyspnoea Cough Haemoptysis Pain Wheeze Complications Chest
X-ray
HRCT Biopsy/histology
Patientswith de¢nite LAM
1 Yes Yes Yes 1Bil P P Notperformed ‘‘lung involement’’
2 Yes Yes Yes 1Bil P P Unavailable ‘‘appearance of
LAM’’
3 Developed bilateralpnuemothoracies under GA and diedwhilst
ventilated 7 days later
P Notperformed LAM
4 Yes Yes 1Lt P,1Chy,
1Pul Haem
P Notperformed LAM
5 Yes Yes Yes Yes 2 Rt P P,RS Multiple cystic
spaces
‘‘proliferation of
immature
muscle’’
6 Yes Yes Yes 2 Rt P,1Lt P P Notperformed ‘‘small cysts in
the lung tissue’’
7 Yes Yes Yes Notperformed LAM
8 Yes Yes Yes 1Bil P,1Chy P Notperformed ‘‘proliferation of
smoothmuscle’’
9 Yes Yes Yes 1Rt P,1Chy,1CE Emph Emphysema ‘‘opinion is of
honeycomb lung’’
10 Yes Yes Yes Yes 1Bil P P Consistent
with LAM
‘‘proliferation of
smoothmuscle’’
Patientswith a probable diagnosis of LAM
11 Yes Yes Yes Yes Yes Thinwalled
cysts.
Notperformed
12 Yes Yes Yes Yes 1Rt P P Lungcysts
and bullae
Notperformed
13 Yes Yes Yes 1Rt P P Honeycomb
pattern
Notperformed
14 Yes 1Chy P,E¡ Cystic changes
of TSC
Notperformed
15 Yes Yes Yes 1Bil P P Thinwalled
cysts
Notperformed
16 Yes Yes Yes Yes 1Rt P,1Lt P Yes Thinwalled
cysts
Notperformed
17 Yes Yes Yes Yes Yes 2 Rt P,1Lt P Yes Notperformed Notperformed
18 Yes Yes Yes Yes Yes Notperformed Notperformed
19 Yes Yes Yes 1RTP RS Notperformed Notperformed
Patientswith a possible diagnosis of LAM
20 Yes Yes Yes Yes Yes 1Rt P P Notperformed Notperformed
21 Yes 1Lt P P Notperformed Notperformed
HRCT: high resolution computerised tomography scan of chest; Rt P: right pnuemothorax; Lt P: left pnuemothorax; Bil P:
bilateral pnuemothorax; Chy: chylothorax; Pul Haem: pulmonary haemorrhage; CE: peri-cardial e¡usion; H: honeycomb ap-
pearance;P: pnuemothorax;RS: reticular shadowing;Emph: emphysema;E¡: pleural e¡usion.
10 RESPIRATORYMEDICINEscreened and found to have normal renal ultrasound
scans, the remaining ¢ve patients have not been
screened. Epilepsy was the commonest neurological
manifestation occurring in 18 (86%) patients, 10 (48%)
had associated learning di⁄culties and six (29%) autistic
spectrum disorder and hyper-activity. Two patients had
giant cell astrocytoma with associated hydrocephalus.
One patient had a mild hemiplegia. Four patients had
asymptomatic hepatic angiomyolipoma. No cardiac
rhabdomyomas had been detected. Four patients had ascoliosis (¢xed in two), but none had undergone surgery
or bracing. All four had a mild course of LAM.
DISCUSSION
The Wessex TS epidemiology study identi¢ed 147 pa-
tients and had a prevalence of one in 23500 on1 January
1997 (personal communication).Only one of these cases
had symptomatic LAM, giving a prevalence of 0?66% for
TABLE 3. Acute surgical and medical treatment, long-term medical treatment, disease course and duration of follow-up (in
parentheses)
Acute/surgical treatment Long-termmedical treatment Disease course (follow-up)
Patientswith a de¢nite diagnosis of LAM
1 Drainage Pleurodesis Oxygentherapy Died from cor pulmonale whilst waiting
for transplant (B25 years after onset of
symptoms)
2 Drainage Pleurodesis Oxygentherapyprogesterone Died fromcor pulmonale, too ill for trans-
plant (B10 years afteronsetof symptoms)
3 Drainage andventilation None Died from respiratory and renal failure
(B1week afteronsetof symptoms)
4 None None Died from massive pulmonary haemor-
rhage (B2 weeks after onset of symp-
toms)
5 Drainage Pleurodesis None Stable (3 years)
6 Drainage Pleurectomy None Remainswell (25 years)
7 None Inhalers (no bene¢t) Improved (23 years)
8 Drainage Pleurectomy None Remainswell (6 months)
9 Lobectomy None Remainswell (38 years)
10 Drainage Pleurodesis Progesterone Remainswell
Patientswith a probable diagnosis of LAM
11 None Atrovent (little bene¢t) Stable (13 years)
12 Drainage Pleurectomy Progesterone Improved (18 years)
13 Drainage Pleurodesis Atrovent (some bene¢t) Remainswell (2 years)
14 Drainage Pleurodesis Progesterone Remainswell (1year)
15 Drainage Pleurodesis None Progressive deterioration (10 years)
16 Drainage Pleurodesis Inhalers (no bene¢t) Progressive deterioration (30 years)
17 Drainage Pleurodesis Progressive deterioration (31years)
18 None Inhalers (no bene¢t) Improved slowly (6 years)
19 Aspiration None Remainswell (2 years)
Patientswith a possible diagnosis of LAM
20 Drainage Pleurodesis None Remainswell (17 years)
21 Drainage None Remainswell (5 years)
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toms soon after. This ¢nding is similar to previous stu-
dies. Dwyer et al. (2) and Torres et al. (7) estimated that
LAM occurs in less than1% of patients withTSC,Castro
et al. (3) a slightly higher incidence of 2?3%.We know we
will have missed some cases of TSC (1), but within the
Wessex population we are less likely to have missed
symptomatic LAM.However, incidental ¢ndings of LAM
have been described on the CXRs and CT scans of en-
tirely asymptomatic TSC patients (2). No study has
screened TSC patients for LAM and the true prevalence
may be higher than that estimated from symptomatic
patients.
Although the numbers in our study were small there
was no di¡erence between patients with de¢nite, prob-
able or possible LAM in presentation, clinical course or
outcome. All the female patients developed symptoms
prior to the menopause and two with de¢nite LAM did
so prepubertally.This shows that LAM inTSC is not con-
¢ned to females of childbearing age.Therehavebeenonly¢ve previous reported cases (2,9^12) of LAM in males
with TSC. None reported changes on HRCT, two had
not been con¢rmed by biopsy and those con¢rmed by
biopsy were reported as being consistent with TSC,
thickened pleurawith cysts or cysts empty or ¢lledwith
£uid.We identi¢ed three males withTSCwho exhibited
signs of lung disease. Patient 7 su¡ered thick pulmonary
secretionswith recurrent chest infections frombirthun-
til puberty only. Lung biopsy was reported as LAM and
led to the diagnosis of TSC but is no longer available for
repeat analysis andhe is not su⁄ciently co-operative for
HRCT. His unusual course must throw some doubt on
the diagnosis of LAM. Patient 18 su¡ered from episodes
of dyspnoea andwheeze from aged 8 years: asthmamed-
ication did not relieve his symptoms and a chest X-ray
showed honeycombing, suggesting LAM. He has never
had HRCT or open lung biopsy. Patient 19 had been
asymptomatic until 32 years when he su¡ered a sponta-
neous pneumothorax.He has had no recurrence (follow-
up 4 years), nor su¡ered any other respiratory symp-
12 RESPIRATORYMEDICINEtoms. His chest X-ray con¢rmed LAM. His karyotype
was found to be 47XXY (Klinefelter’s syndrome), possi-
bly explaining his presentationwith a lung disease that is
normally limited to females.We would conclude that in
anymale withTSC in whom the diagnosis of LAM is sus-
pected, other pulmonary diagnoses must be excluded,
chromosomal analysis, HRCTand preferably lung biopsy
shouldbeperformed to con¢rm the diagnosis since LAM
in phenotypic males is very rare.The age of diagnosis of
TSC in thepatients in this serieswas17 years, slightlyold-
er than is usual.This may be a chance ¢nding because of
the small numbers, but it is consistent with previous ob-
servations (13) that patients diagnosed with pulmonary
TSC often have otherwisemild TSC, often delaying diag-
nosis.We found the median age to onset of pulmonary
symptoms (20 years), and the subsequent diagnosis of
LAM (25 years) to be earlier than previously reported
(2,3), although the delay between onset and diagnosis (6
years) was similar. The earlier age of diagnosis found in
our small group of patients may be a chance ¢nding, it is
possible that due to their genetic predisposition to this
disease, patients with TSC develop LAM at a younger
age thanpatientswithout TSC, but Johnson (4) reported
themean age of onset of LAM to be 34 years.
We observed therange of recognizedpresentations of
LAM, butwe also observed two raremanifestations. Pa-
tient14 in the current series presentedwith cardiac tam-
ponade and a haemopericardium, pericardial e¡usion in
LAMhas only been reported once (14), in a patientwith-
out TSC.Patient four su¡ered amassive pulmonary hae-
morrhage resulting in sudden death. To our knowledge
this has not been previously reported in the literature.
LAM is described as a generalised lung disease a¡ecting
all zones of the lung equally (15).This may not always be
true inTSC: patient 9 had severe persistent disease for
several years until she underwent a lobectomy, following
which she has remained asymptomatic for 38 years.
Since few patients with LAM and TSC have been de-
scribed, it is di⁄cult to summarize its associations with
the other clinical stigmata of TSC. In Castro’s study (3)
eight out of nine of patients su¡ered from severe renal
disease with haemorrhage into AML prior to diagnosis
of their lung complications, suggesting a possible associa-
tion between symptomatic renal disease and LAM.We
looked for other clinical associations of TSC in this series
of 21patients and compared themwith the 395 patients
known to the Bath TSC clinic, to see if there was any
phenotype at high risk of developing LAM. If this proved
to be the case it might form a basis for screening high-
risk patients. There was no signi¢cant di¡erence be-
tween the two groups in the prevalence of any other
manifestations of TSC including renal AML. We there-
fore propose that, at the present time, there are no
prognostic factors that assist in predicting which indivi-
duals withTSC are at greatest risk of developing lung dis-
ease, but that it is rare inmen and children.Treatment is predominantly symptomatic. Johnson (4)
suggested that air£ow obstruction was often helped by
inhaled b-agonists, anecdotally this was not the case in
our patients. In our patients there was a variable re-
sponse to hormone therapy. Lung transplantation is an-
other treatment option but the presence of systemic
disease and occasionally of previous pleurodesis limits
the number of patients in whom this is a viable option.
In three previously reported cases LAM has recurred in
a transplanted lung (16^18). We do agree with Johnson
that the most pressing issue in the management of LAM
is to determine the place of hormonal therapy.
LAM, although rare, is an important cause of mortal-
ity inTSC. Shepherd et al. (19) found lung disease to be
the fourth most common cause of early mortality in
TSC. Average duration of survival from the time of diag-
nosis LAMwas reported to be 4?8 years in1971 (2).More
recent studies estimate survival to be nearer to10 years
and there are reports of apparent spontaneous resolu-
tion. In this study the clinical course of LAM inTSCwas
extremely variable.
Screening for LAM in patients withTSC remains con-
troversial.There are no factors that can be used to iden-
tify those patients at greatest risk of developing LAM,
other than being female. HRCT is likely to be the most
sensitive tool for recognising LAM, but it is not known
whether changes are consistently seen on chest X-ray
or HRCT before the development of symptoms. Itwould
presently be unwise to screen all females with TSC for
evidence of LAM until further data on the investigation,
natural history and e⁄cacy of early intervention are
available.There is an argument for considering screening
female patientswithTSC for lung diseasebefore theyun-
dergo anaesthesia or £y, as these circumstancesmaypre-
cipitate acute problems. We do not know the best
method to do this.
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